HEMATOLOGICAL MALIGNANCIES: LEUKEMIAS, LYMPHOMAS AND MYELOMAS

VolverGo back

Resultados 82 results. LastUpdate Updated on 05/02/2023 [08:36:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



previousPage Page2/4 nextPage   results/page


METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA

Publication No.: US2023027184A1 26/01/2023

Applicant:

GENENTECH INC [US]
ABBVIE INC [US]

US_2023000889_PA

Absstract of: US2023027184A1

Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein are methods of managing a cytopenia in such patient.

traducir

INHIBITORS OF ENL/AF9 YEATS

Publication No.: US2023027198A1 26/01/2023

Applicant:

UNIV ROCKEFELLER [US]
BRIDGE MEDICINES LLC [US]

KR_20220129554_PA

Absstract of: US2023027198A1

Methods and compositions for treating leukemia are disclosed. Acylated 6-aminoindoles, acylated 6-aminopyrrolopyridines and acylated 3-aminopyrrolo[3,2-c]pyridazines of the following formulainhibit ENL/AF9 YEATS and are therefore useful for treating leukemia.

traducir

NEXT-GENERATION SEQUENCING DIAGNOSTIC PLATFORM AND RELATED METHODS

Publication No.: US2023028058A1 26/01/2023

Applicant:

OHIO STATE INNOVATION FOUNDATION [US]

WO_2021126896_A1

Absstract of: US2023028058A1

A system and method for accurate determination of sequence variants from noisy sequencing data, including single nucleotide variants and structural variants of the internal tandem duplication type. This system expands the utility of inexpensive sequencing instruments which stream relatively high-error output sequences in real time, such that they may be used in high-stakes contexts, such as clinical cancer care. An example application is Acute Myeloid Leukemia (AML), where healthcare providers may need to make decisions in hours, is provided.

traducir

14-3-3 PROTEIN MODULATORS AS ANTITUMOR AGENTS

Publication No.: WO2023001942A1 26/01/2023

Applicant:

RAPPOSELLI SIMONA [IT]
GAUDIO EUGENIO [CH]
DAL PIAZ FABRIZIO [IT]

Absstract of: WO2023001942A1

The invention relates to a 2-oxoindole compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are, independently from each other, hydrogen,1H-imidazolyl, thienyl and 1-methyl-1H-imidazolyl, 2-methyl-1H-imidazolyl,2-aminopyridinyl, 1H-pyrazolyl, with the proviso that one of R1 and R2 is hydrogen; or R1 and R2 together form 9H-fluorene R3 is hydrogen, (C1-C3)alkyl, halogen or NO2; for use as a 14-3-3 protein modulator of a tumor selected from the group consisting of a lymphoma, chronic lymphocytic leukaemia (CLL), Ewing sarcoma, colon cancer, melanoma and anaplastic thyroid cancer (ATC). The invention relates also new 2-oxoindole compound of Formula (I) or a pharmaceutically acceptable salt thereof..

traducir

POLYSUBSTITUTED PURINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Publication No.: WO2023000708A1 26/01/2023

Applicant:

UNIV CHINA PHARMA [CN]

CN_113549076_A

Absstract of: WO2023000708A1

Disclosed are a polysubstituted purine compound as shown in formula (I), and a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. Also disclosed is that the compound has an obvious inhibitory effect on RNA adenosine deaminase 1 (ADAR1) and can be used for preventing and/or treating cancer or tumor-related diseases caused by abnormal activity of such enzymes, especially prostate cancer, leukemia, breast cancer, multiple myeloma, lung cancer, stomach cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer, human glioma and other diseases.

traducir

TARGETING DOT1L AND SMARCA4/2 FOR THE TREATMENT OF MLLR LEUKEMIA

Publication No.: WO2023004283A1 26/01/2023

Applicant:

DANA FARBER CANCER INST INC [US]

Absstract of: WO2023004283A1

Disclosed is a method of treating cancer with a compound that possesses degradation activity against SMARCA4/2 in combination with a DOT1L r inhibitor.

traducir

CXCR4 MODULATORS AND USES RELATED THERETO

Publication No.: WO2023003862A1 26/01/2023

Applicant:

UNIV EMORY [US]

Absstract of: WO2023003862A1

CXCR4 antagonists and pharmaceutical formulations thereof are disclosed. The compounds and pharmaceutical formulations disclosed herein can be used to antagonize the CXCR4 pathway for mobilizing stem cells or treating a condition, disorder, or disease associated with the CXCR4 pathway. Exemplary conditions, disorders, and diseases relevant to this disclosure include HIV infections, WHIM syndrome, Waldenström macroglobulinemia, chronic neutropenia, primary immune-deficiency, aplastic anemia, hypoplastic myelodysplastic syndrome, acute respiratory distress syndrome (ARDS), ankylosing spondylitis, autoimmune diseases, and cancers.

traducir

CHEMICAL COMPOSITIONS AND METHODS OF USE

Publication No.: US2023022417A1 26/01/2023

Applicant:

LIQUID BIOPSY RES LLC [KN]

MX_2020000785_A

Absstract of: US2023022417A1

The present invention is directed to methods for detecting a plasma cell dyscrasia like myeloma or MGUS, methods for determining whether a plasma cell dyscrasiais stable or progressive, methods for determining a risk for disease relapse, and methods for determining a response by a subject having a plasma cell dyscrasia to a therapy.

traducir

METHODS

Publication No.: US2023021548A1 26/01/2023

Applicant:

AUTOLUS LTD [GB]

US_2023018688_PA

Absstract of: US2023021548A1

The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.

traducir

METHOD FOR DIAGNOSING CUTANEOUS T-CELL LYMPHOMA DISEASES

Publication No.: US2023028910A1 26/01/2023

Applicant:

SCAILYTE AG [CH]
UNIV ZUERICH [CH]

WO_2021129976_A1

Absstract of: US2023028910A1

The present invention relates to a method for diagnosing Sézary syndrome or mycosis fungoides in a subject. The present invention further relates to a method for determining the frequency of Sézary signature cells and/or mycosis fungoides cells in a sample. Further, the present invention relates to a computer-implemented method comprising a classifier algorithm to determine the frequency of Sézary signature cells and/or mycosis fungoides cells. In addition the present invention relates to a panel of biomarkers that can be used for the diagnosis of Sézary syndrome or mycosis fungoides.

traducir

MULTIPLE MYELOMA COMBINATION THERAPIES BASED ON PROTEIN TRANSLATION INHIBITORS AND IMMUNOMODULATORS

Publication No.: US2023028293A1 26/01/2023

Applicant:

SHERBENOU DANIEL [US]
WALKER ZACHARY [US]
IDLER BEAU [US]
UNIV COLORADO REGENTS [US]

WO_2021119023_A1

Absstract of: US2023028293A1

Multiple myeloma (MM) combination therapies based on protein translation inhibitors, immunomodulators, and bromodomain extra-terminal inhibitors. Methods are provided for treating multiple myeloma in a subject, including administering a therapeutically effective amount of at least one protein translation inhibitor and a therapeutically effective amount of at least one immunomodulatory drug (IMiD), administering a therapeutically effective amount of at least one protein translation inhibitor and a therapeutically effective amount of at least one BET inhibitor, and/or administering a therapeutically effective amount of at least one IMiD and a therapeutically effective amount of at least one BET inhibitor.

traducir

METHODS

Publication No.: US2023027993A1 26/01/2023

Applicant:

AUTOLUS LTD [GB]

US_2023018688_PA

Absstract of: US2023027993A1

The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.

traducir

CANCER TREATMENTS TARGETING CANCER STEM CELLS

Publication No.: US2023023124A1 26/01/2023

Applicant:

REMEDY PLAN INC [US]

JP_2022553865_PA

Absstract of: US2023023124A1

Disclosed are compounds, methods, compositions, uses, and kits that allow for treating cancer. In some embodiments, the compounds are used to treat diseases or disorders. The compounds may treat cancer by targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, lymphoma, liver cancer, endometrial cancer, leukemia, or multiple myeloma. Disclosed are compounds, methods, compositions, uses, and kits that may be used in regenerative medicine. The compounds utilized in the disclosure are of Formula (0) and (I).

traducir

N-ACYL-{4-(4-ARYL-PHENYL)SULFONYLMETHYLPIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE

Publication No.: US2023022917A1 26/01/2023

Applicant:

MODERN BIOSCIENCES LTD [GB]

JP_2022528799_A

Absstract of: US2023022917A1

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds of the following formula (collectively referred to herein as NASMP compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), Hidradenitis suppurativa, autoimmune hepatitis, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

traducir

IMMUNOTHERAPEUTIC COMPOSITIONS

Publication No.: US2023022956A1 26/01/2023

Applicant:

GLAXOSMITHKLINE BIOLOGICALS SA [BE]
VARIATION BIOTECHNOLOGIES INC [CA]

Absstract of: US2023022956A1

The present disclosure provides compositions and methods useful for treating Glioblastoma Multiforme (GBM) which comprise virus-like particles (VLPs) comprising murine leukemia virus (MLV) core proteins and the human cytomegalovirus epitopes, gB and pp65, formulated with an adjuvant comprising a saponin and a TLR4 agonist.

traducir

MODULATORS OF PROGRAMMED DEATH-LIGAND-1 AND/OR PROGRAMMED DEATH-LIGAND-2

Publication No.: US2023029187A1 26/01/2023

Applicant:

SOUTHERN RES INST [US]

AU_2020396100_PA

Absstract of: US2023029187A1

The present disclosure is concerned with dipeptide compounds for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanomas, gliomas, leukemias, lymphomas, chronic myeloproliferative disorders, myelodysplastic syndromes, myeloproliferative neoplasms, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

traducir

COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA

Publication No.: EP4121430A1 25/01/2023

Applicant:

FLASH THERAPEUTTICS LLC [US]

TW_202200583_PA

Absstract of: WO2021184154A1

Provided herein are compounds for treating acute myeloid leukemia or inhibiting recurrence of acute myeloid leukemia and for inhibiting growth of and/or killing leukemic stem cells.

traducir

COMBINATION THERAPY FOR ACUTE MYELOID LEUKEMIA

Publication No.: EP4121051A1 25/01/2023

Applicant:

CELGENE CORP [US]

CN_115515582_PA

Absstract of: WO2021188387A1

Provided herein are methods of treatment of AML comprising administering 2-(4- chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)methyl)-2,2- difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a combination therapy.

traducir

SOLID FORM OF PYRAZINE SUBSTITUTED NICOTINAMIDE, AND PREPARATION AND USE THEREOF

Publication No.: EP4122928A1 25/01/2023

Applicant:

SHENZHEN TARGETRX INC [CN]

CN_115413277_PA

Absstract of: EP4122928A1

Provided are a crystal form of a free base or a pharmaceutically acceptable salt of (R)-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-fluoropyrrolidin-1-yl)-5-(pyrazin-2-yl)nicotinamide (compound A), a preparation method therefor, and use of the compound in preparation of drugs for treating diseases mediated by Bcr-Abl kinase and mutants thereof, such as chronic granulocytic leukemia. Also provided are a method for preparing compound A, and a preparation containing compound A.

traducir

METHOD FOR DETECTING INDICATOR OF T-CELL LYMPHOMA AND UTILIZATION THEREOF

Publication No.: EP4122494A1 25/01/2023

Applicant:

MANDOM CORP [JP]
UNIV OSAKA [JP]
UNIV NAGOYA CITY PUBLIC UNIV CORP [JP]

KR_20220109441_A

Absstract of: EP4122494A1

The present invention provides a novel method for detecting an indicator of T cell lymphoma. The method for detecting an indicator of T cell lymphoma includes the step of detecting acetylated tubulin in a T cell that has been collected from a subject.

traducir

System and Method for determining lymphoma

Publication No.: KR20230010884A 20/01/2023

Applicant:

가톨릭대학교산학협력단

Absstract of: KR20230010884A

본 명세서는 복수의 타깃 세포들에 대한 Ki-67 염색 패턴 이미지를 입력받는 입력부, Ki-67 염색 패턴 이미지의 염색 강도를 분석하여, 복수의 타깃 세포들을 복수의 그룹들으로 분류하는 이미지 분석부, 복수의 그룹들 각각에 포함된 타깃 세포들의 개수를 기초로, 복수의 타깃 세포들에 대한 림프종 타입이 미만성 거대 B세포 림프종(DLBCL, Diffuse large B-cell lymphoma)인지 또는 버킷 림프종(BL, Burkitt lymphoma)인지를 판단하는 판단부를 포함하는 림프종 판단 시스템 및 그에 대한 방법을 제공한다.

traducir

CDK6/DYRK2 dual-target inhibitor, and preparation method therefor and use thereof

Publication No.: AU2021422370A1 19/01/2023

Applicant:

JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD

WO_2022156059_A1

Absstract of: AU2021422370A1

Disclosed are a compound as represented by the following general formula (I) or a pharmaceutically acceptable salt thereof. Further disclosed are a method for preparing the above-mentioned compound and the use thereof in preventing and/or treating diseases related to cancer or tumors, in particular diseases such as breast cancer, prostate cancer, lung cancer, multiple myeloma, leukemia, gastric cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer and human glioma. The compound of the present invention is expected to be developed into a new generation of anticancer drugs.

traducir

Anti-tumor combination therapy comprising anti-CD19 antibody and polypeptides blocking the SIRPalpha-CD47 innate immune checkpoint

Publication No.: AU2021298106A1 19/01/2023

Applicant:

MORPHOSYS AG
GILEAD SCIENCES INC

US_2023014026_PA

Absstract of: AU2021298106A1

The present disclosure is directed to a combination therapy comprising an antibody or antibody fragment specific for CD19 and a polypeptide that blocks the SIRPα-CD47 innate immune checkpoint for use in the treatment of cancer, in particular hematological cancer such as leukemia or lymphoma.

traducir

Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint

Publication No.: US2023014026A1 19/01/2023

Applicant:

MORPHOSYS AG [DE]
GILEAD SCIENCES INC [US]

AU_2021298106_PA

Absstract of: US2023014026A1

The present disclosure is directed to a combination therapy comprising an antibody or antibody fragment specific for CD19 and a polypeptide that blocks the SIRPα-CD47 innate immune checkpoint for use in the treatment of cancer, in particular hematological cancer such as leukemia or lymphoma.

traducir

METHODS

Nº publicación: US2023018688A1 19/01/2023

Applicant:

AUTOLUS LTD [GB]

US_2023019650_PA

Absstract of: US2023018688A1

The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TOR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.

traducir

previousPage Page2/4 nextPage results/page

punteroimgGo back